Antihemophilic factor (recombinant), single chain is a Recombinant Protein owned by SK Chemicals, and is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing.

CSL-627 is a single chain recombinant factor VIII (rFVIII). Coagulation factors are the proteins responsible for the formation of blood clots. Coagulation factor VIII circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from Von Willebrand factor. The active protein interacts with another coagulation factor called factor IX.

The revenue for Antihemophilic factor (recombinant), single chain is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Antihemophilic factor (recombinant), single chain NPV Report.

Antihemophilic factor (recombinant), single chain is originated and owned by SK Chemicals. CSL is the other company associated in development or marketing of Antihemophilic factor (recombinant), single chain.

Antihemophilic factor (recombinant), single chain Overview

Antihemophilic factor (recombinant) (Afstyla, Afsteyela, Abstyla ) is a single chain recombinant factor VIII (rFVIII). Afstyla is formulated as lyophilized powder for solution for intravenous route of administration. Afstyla is indicated in adults and children with hemophilia A for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; control and prevention of bleeding episodes; and perioperative management of bleeding (surgical prophylaxis).

CSL Overview

CSL discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.

The company reported revenues of (US Dollars) US$10,561.9 million for the fiscal year ended June 2022 (FY2022), an increase of 2.4% over FY2021. The operating profit of the company was US$2,927.4 million in FY2022, compared to an operating profit of US$3,130 million in FY2021. The net profit of the company was US$2,254.7 million in FY2022, compared to a net profit of US$2,375 million in FY2021.

Quick View – Antihemophilic factor (recombinant), single chain

Report Segments
  • Innovator (NME)
Drug Name
  • Antihemophilic factor (recombinant), single chain
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.